Evidence map›Paper›PMID 41647779›Full record

ArticleESMO real world data and digital oncology2024

Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data.

M J Emmett, J C F Quintanilha, R P Graf, G Li, H Tukachinsky, A B Schrock, S Morley, V A Fisher, G R Oxnard, C H Lieu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M J EmmettDivision of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
J C F QuintanilhaFoundation Medicine, Cambridge.
R P GrafFoundation Medicine, Cambridge.
G LiFoundation Medicine, Cambridge.
H TukachinskyFoundation Medicine, Cambridge.
A B SchrockFoundation Medicine, Cambridge.
S MorleyFoundation Medicine, Cambridge.
V A FisherFoundation Medicine, Cambridge.
G R OxnardFoundation Medicine, Cambridge.
C H LieuDivision of Medical Oncology, University of Colorado Denver Anschutz Medical Campus and University of Colorado Cancer Center, Aurora.
P A MyerDivision of Gastroenterology, Department of Medicine, Montefiore Medical Center, Albert Einstein Cancer Center, New York, USA.
S J KlempnerDivision of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with metastatic colorectal cancer (mCRC) with Materials and methods: This study utilized a de-identified mCRC clinicogenomic database from ∼280 US cancer clinics between March 2014 and April 2023. We examined real-world progression-free survival (rwPFS) and overall survival (rwOS) between patients with and those without pre-specified genomic alterations (PSGAs) by Cox models and an adjusted risk score. Genomic alterations were also compared between samples collected before and after EGFR mAb therapy. Results: Nearly, one-third of microsatellite stable (MSS) Conclusions: Detection of genomic resistance alterations in MSS

Indexed as

colorectal cancercomprehensive genomic profilingEGFRnext-generation sequencingreal-world data

Identifiers

PMID41647779
PMCPMC12836733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.